- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01281605
Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes
Comparison of Two Titration Programs of Adding Insulin Detemir to Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes Patients
연구 개요
상세 설명
This is a 24-week, prospective, open-label, randomized, parallel-group study conducted in approximately 200 patients with type 2 diabetes in the Taiwan. The effectiveness of insulin detemir will be assessed at baseline and at 12 and 24 weeks after initiation of study prescription. The safety will be followed during the 24-week study period.
Inclusion criteria:
Patients must meet all of the following criteria:
- Men and women with type 2 diabetes.
- 20 years of age.
- Patients who have received stable doses of any OADs for at least 10 weeks prior to the screening visit.
- Patients with inadequate glycemic control (HbA1C >=7% and < 11%).
- Patients who are willing and able to cooperate with study and give signed informed consent.
After enrollment, eligible patients will be randomized in a 1:1 ratio to one of the following titration algorithms:
- Active titration algorithm: contact with investigator by telephone weekly.
- Usual titration algorithm: contact with investigator only at routine study visit.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Hsinchu, 대만, 30067
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Hsinchu branch
-
Taipei, 대만, 10449
- Mackay Memorial Hospital
-
Taitung, 대만, 95054
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Taitung branch
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Patients must meet all of the following criteria:
- Men and women with type 2 diabetes.
- 20 years of age.
- Patients who have received stable doses of any OADs for at least 10 weeks prior to the screening visit.
- Patients with inadequate glycemic control (HbA1C >=7% and < 11%).
- Patients who are willing and able to cooperate with study and give signed informed consent.
Exclusion Criteria:
- Patients with type 1 diabetes.
- Renal dialysis patients.
- History of hypoglycemia unawareness.
- Patients who had received any insulin for more than 2 weeks or who have received insulin treatment within 4 weeks prior to screening visit.
- Patients who have received any investigational products (drug and device) within 4 weeks prior to screening visit.
- Patients hypersensitive with insulin detemir or its excipients.
- Patients who are currently pregnant/lactating,or who are preparing for pregnancy or lactation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Active titration algorithm
titrate insulin dose by contacting with investigator by telephone weekly.
|
Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(<110mg/dl).
다른 이름들:
|
|
실험적: Usual titration algorithm
contact with investigator only at routine study visit.
|
All patients will be instructed to self-measure fasting capillary blood glucose.
The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values.
the daily insulin dose should be increased by 2 IU/day if the FPG>=110mg/dL, and by 4 IU/day if the FPG>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG < 70 mg/dL.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To compare the change in HbA1c between two study groups at Week 24.
기간: 24 weeks
|
compare the change in HbA1c between two study groups after 24 weeks treatment.
|
24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To compare the change in HbA1C between two study groups at Week 12.
기간: 12 weeks
|
compare the change in HbA1C between two study groups after 12 of treatment.
|
12 weeks
|
|
To compare the proportion of patients achieving HbA1C <7% at Week 24
기간: 24 weeks
|
compare the proportion of patients achieving HbA1C <7% after 24 weeks treatment
|
24 weeks
|
|
To compare the changes in fasting plasma glucose (FPG) at Week 12 and 24.
기간: 24 weeks
|
compare the changes in fasting plasma glucose (FPG) after 12 and 24 treatment.
|
24 weeks
|
|
To compare the change in body weight at each visit
기간: 24 weeks
|
compare the change in body weight at each visit
|
24 weeks
|
|
To evaluate the incidence of adverse events.
기간: 24 weeks
|
evaluate the incidence of adverse events including hypoglycemia and any other adverse event.
|
24 weeks
|
공동 작업자 및 조사자
수사관
- 연구 의자: Sung-Chen Liu, MD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital
- 수석 연구원: Hui-Fang Chang, MD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Hsinchu branch
- 수석 연구원: Ke-Yan Wu, MD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital Taitung branch
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 10M MHIS112
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .